- A Case of Ioslated TSH Deficiency.
-
Hyun Kim, Won Seob Kim, Soo Jin Choi, Dong Yoon Kim, Se Hyun Kim, Seung Min Park, Wan Koo Lee, Young Nam Kim
-
J Korean Endocr Soc. 1999;14(2):392-395. Published online January 1, 2001
-
-
-
 Abstract
 PDF
- Although complete or partial deficiency of anterior pituitary hormone is well known,but isolated TSH deficiency is relatively rare throughout the world. Hypothyroidism due to isolated TSH deficiency is diagnosed by 1)symptoms or signs of thyroid deficiency, 2)demonstration of an absent or impaired TSH response to TRH stimulation, 3)intact other pituitary hormones. We report a case of hypothyroidism due to isolated TSH deficiency. The patient was 75 years old man and his complaints were generalized edema and weight gain. On laboratory study, T3, T4, TSH was low and TSH response to TRH stimulation was blunted, but other piutuitary hormones were intact. After thyroxine replacement, TFT and his symptoms were recovered.
- Comparison of the Effectiveness and Hypocalcemia Risk of Antiresorptive Agents in Patients with Hypercalcemia of Malignancy
-
Sung Hye Kong, Seung Shin Park, Jung Hee Kim, Sang Wan Kim, Se Hyun Kim, Jee Hyun Kim, Chan Soo Shin
-
Received August 2, 2024 Accepted October 29, 2024 Published online February 4, 2025
-
DOI: https://doi.org/10.3803/EnM.2024.2132
[Epub ahead of print]
-
-
Abstract
PDF
 Supplementary Material PubReader  ePub
- Background
Hypercalcemia of malignancy (HCM), a major metabolic complication of cancer, is often managed with bisphosphonates (BP) and, increasingly, with denosumab. We aimed to compare the effectiveness and safety of denosumab with that of BP, with or without calcitonin, in treating HCM.
Methods
This retrospective cohort study was conducted at a tertiary hospital from 2017 to 2022 and included 317 patients treated for HCM. Participants were divided into three treatment groups: denosumab, intravenous (IV) BP only, and IV BP combined with calcitonin. The primary outcomes measured were changes in calcium levels and the incidence of hypocalcemia. Analysis of covariance was used to adjust for age, sex, body mass index, creatinine level, type of malignancy, and the use of furosemide and steroids.
Results
The mean participant age was 65 years, and 37.5% were female. After adjustment, both denosumab and IV BPs were found to effectively lower calcium levels. Denosumab led to a decrease of 2.0 mg/dL (−15.9%), while IV BP alone resulted in a reduction of 1.8 mg/dL (−13.9%). The largest reduction, of 2.7 mg/dL (−20.9%), occurred with IV BP and calcitonin. Both denosumab and IV BP+calcitonin yielded their lowest calcium levels within 48 hours, whereas the IV BP only group reached a nadir within 72 hours. Despite these differences in treatment effectiveness, hypocalcemia occurred significantly less frequently in the denosumab group compared to the other groups.
Conclusion
Denosumab and IV BP were similarly effective in reducing calcium levels. However, IV BP combined with calcitonin yielded a more rapid and pronounced decrease.
|
KES
